The science existed.
The incentives didn't.
So we fixed them — permanently.
We built XIT because the world has been engineered to thrive on suffering.
We're engineering it to suffer thriving.
Most funding goes to treatments because treatments generate recurring profit — cures do not. We have restructured the economics of medicine to ensure that curing pediatric cancer is the most profitable endeavor possible.
The Flywheel — Realigning the Flow of Capital
In the traditional market, biological manufacturing profits exit the system to shareholders, creating a disincentive to develop definitive, single-dose cures. The XIT structure closes the loop and feeds it back.
Traditional Pharma Model
Profits distributed away from R&D.
XIT VITE Flywheel
51% of dividends catalyze next-gen cures.
The V.I.T.E. Framework
(V)ertically (I)ntegrated (T)rivalent (E)cosystem
Three interlocking entities designed for permanence, governed with integrity, and built at scale to act as the Ultimate Bio Reactor for humanity. Click on an entity below to understand its role.
XIT Foundation
Nonprofit Philanthropic Foundation. Holds permanent majority governance.
Xcession Biologics
For-Profit CDMO. Generates revenue, attracts investors, builds SPRINTD.
Xcession Institute of Technology
Advanced Research Lab. Uses AI to discover new RNA/DNA cures.
XIT Foundation
The nonprofit cornerstone of our trivalent ecosystem. It holds permanent majority governance over Xcession Biologics and Xcession Institute of Technology. Because the Foundation can never be outvoted, the company can never be pressured by outside investors to prioritize a profitable chronic treatment over an actual, definitive cure for pediatric cancer.
The SPRINTD Platform
Secure Printer for Rapid Individualized Nucleic-acid Targeted Delivery. A distributed, compact, automated platform for on-demand manufacturing of genetic medicines. Built by Xcession Biologics to democratize access to nucleic-acid ELN medicine.
Evolution of Biological Printers
Comparing the XIT SPRINTD model against legacy centralized mRNA manufacturing paradigms.
| Dimension | Legacy Centralized Hubs | SPRINTD Distributed Network |
|---|---|---|
| Architecture | Massive, centralized bioreactor facilities requiring massive capital expenditure. | Compact, Automated, Distributed. Places manufacturing at the point of care or regional nodes. |
| Target Production | High-volume, generic treatments for broad populations. | Individualized & Rare Diseases. Optimized for rapid, low-batch custom nucleic-acid medicines. |
| Economic Incentive | Maximizing shareholder value through recurring revenue streams (treatments). | Curative Pipeline. CDMO profits are locked via Foundation governance to fund next-gen cures. |
| Supply Chain | Vulnerable to global logistical chokepoints and cold-chain breakdowns. | Resilient & Reshored. On-demand local generation mitigates global supply shocks. |
Why Texas?
A strategic, purpose-driven geographic advantage. Building the ultimate bioreactor requires the ultimate ecosystem of medical talent, funding, and clinical access.
Global Medical Hub
Texas Medical Center is the world's largest (10M+ patient visits). Access to Helix Park (TMC3) labs and Texas Children's for pediatric oncology.
Unmatched Funding Power
CPRIT provides over $4.05 billion for cancer research. Backed by JETI and TEF enterprise incentive funds to drive capital investment.
AI & Talent Engine
100,000+ biotech professionals, 5,000 STEM grads annually. Deep partnerships with UT Southwestern for AI-driven oncology discovery.
Large Pediatric Population
Major academic centers available, yet no currently oversaturated CRISPR-focused pediatric translational hub. Opportunity to lead, not just compete.
Cost Efficiency = Mission Focus
Lower operating burn compared to Cambridge/SF. Capital goes directly toward research and SPRINTD manufacturing instead of excessive rent.
"Texas-Built for Kids" Narrative
Aligns perfectly with national reshoring of biologics and national biotech security themes. A powerful positioning for federal initiatives like ARPA-H.